Hypoxic stress suppresses lung tumor-secreted exosomal miR101 to activate macrophages and induce inflammation.
Animals
Biomarkers, Tumor
/ metabolism
CDC2 Protein Kinase
/ metabolism
Cell Line, Tumor
Cell Proliferation
/ genetics
DNA-Binding Proteins
/ metabolism
Exosomes
/ metabolism
Female
Gene Expression Regulation, Neoplastic
Inflammation
/ genetics
Interleukin-1
/ metabolism
Interleukin-6
/ metabolism
Lung Neoplasms
/ genetics
Macrophage Activation
/ genetics
Macrophages
/ metabolism
Mice, Inbred C57BL
MicroRNAs
/ genetics
Transcription Factors
/ metabolism
Tumor Hypoxia
/ genetics
Xenograft Model Antitumor Assays
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
06 08 2021
06 08 2021
Historique:
received:
08
09
2020
accepted:
13
05
2021
revised:
12
05
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
27
1
2022
Statut:
epublish
Résumé
Hypoxia promotes inflammation in the tumor microenvironment. Although hypoxia-inducible factor 1α (HIF1α) is a master modulator of the response to hypoxia, the exact mechanisms through which HIF1α regulates the induction of inflammation remain largely unclear. Using The Cancer Genome Atlas Lung Squamous Cell Carcinoma (TCGA-LUSC) database, we divided patients with LUSC into two groups based on low or high HIF1α expression. After analyzing the differentially expressed genes in these two groups, we found that HIF1α was positively correlated with interleukin 1A (IL1A) and IL6 expression. Our in vitro study showed that hypoxic stress did not induce IL1A or IL6 expression in tumor cells or macrophages but dramatically enhanced their expression when co-cultured with tumor cells. We then investigated the effect of tumor-derived exosomes on macrophages. Our data suggested that the changes in miR101 in the tumor-derived exosomes played an important role in IL1A and IL6 expression in macrophages, although the hypoxic stress did not change the total amount of exosome secretion. The expression of miR101 in exosomes was suppressed by hypoxic stress, since depletion of HIF1α in tumor cells recovered the miR101 expression in both tumor cells and exosomes. In vitro, miRNA101 overexpression or uptake enriched exosomes by macrophages suppressed their reprogramming into a pro-inflammatory state by targeting CDK8. Injection of miR101 into xenografted tumors resulted in the suppression of tumor growth and macrophage tumor infiltration in vivo. Collectively, this study suggests that the HIF1α-dependent suppression of exosome miR101 from hypoxic tumor cells activates macrophages to induce inflammation in the tumor microenvironment.
Identifiants
pubmed: 34362882
doi: 10.1038/s41419-021-04030-x
pii: 10.1038/s41419-021-04030-x
pmc: PMC8346509
doi:
Substances chimiques
Biomarkers, Tumor
0
DNA-Binding Proteins
0
Interleukin-1
0
Interleukin-6
0
MIRN101 microRNA, human
0
MicroRNAs
0
SUB1 protein, human
0
Transcription Factors
0
CDC2 Protein Kinase
EC 2.7.11.22
CDK1 protein, human
EC 2.7.11.22
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
776Informations de copyright
© 2021. The Author(s).
Références
Nat Immunol. 2016 Jul 19;17(8):906-13
pubmed: 27434011
Nat Rev Immunol. 2002 Aug;2(8):569-79
pubmed: 12154376
Cancer Res. 2016 Apr 1;76(7):1770-80
pubmed: 26992424
J Clin Invest. 2016 Oct 3;126(10):3689-3698
pubmed: 27525434
Front Immunol. 2019 Jun 07;10:1197
pubmed: 31231372
Int J Cancer. 2010 Jun 15;126(12):2863-73
pubmed: 19790197
Cancer Cell. 2014 Apr 14;25(4):501-15
pubmed: 24735924
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
Sci Rep. 2018 Jan 16;8(1):829
pubmed: 29339789
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
Nature. 2008 Sep 25;455(7212):547-51
pubmed: 18794900
J Immunol. 2013 Dec 15;191(12):6250-60
pubmed: 24227773
Am J Transl Res. 2018 Nov 15;10(11):3310-3321
pubmed: 30662588
Blood. 2012 Jan 19;119(3):756-66
pubmed: 22031862
J Vis Exp. 2016 Jul 17;(113):
pubmed: 27500972
Genome Biol. 2014;15(12):550
pubmed: 25516281
Oncotarget. 2017 Sep 13;8(63):106538-106550
pubmed: 29290969
Mol Cancer. 2014 Nov 26;13:256
pubmed: 25428807
Cancer Metastasis Rev. 2010 Jun;29(2):285-93
pubmed: 20393783
Cancer Metastasis Rev. 2013 Jun;32(1-2):3-4
pubmed: 23070754
Cancer Res. 2014 Sep 1;74(17):4720-30
pubmed: 24958470
Proteomes. 2013 Sep 1;1(2):87-108
pubmed: 24860738
Cancer Lett. 2016 May 28;375(1):51-61
pubmed: 26945971
Nat Commun. 2018 Dec 19;9(1):5395
pubmed: 30568162
Curr Opin Cell Biol. 2014 Aug;29:116-25
pubmed: 24959705
Cancer Res. 2017 Dec 1;77(23):6480-6488
pubmed: 29162616
Oncogene. 2019 Jun;38(26):5158-5173
pubmed: 30872795
Front Oncol. 2018 Aug 28;8:344
pubmed: 30211122
Eur Urol Focus. 2016 Jun;2(2):210-218
pubmed: 28723537
Semin Immunopathol. 2011 Sep;33(5):441-54
pubmed: 21688197
Immunol Rev. 2013 May;253(1):167-84
pubmed: 23550646
Cancer Res. 2017 Jul 15;77(14):3846-3856
pubmed: 28588009
Mol Cancer. 2019 Mar 30;18(1):57
pubmed: 30925935
Genes Cells. 2017 Mar;22(3):265-276
pubmed: 28151579
Cancer Res. 2018 Aug 15;78(16):4586-4598
pubmed: 29880482
Adv Biol Regul. 2015 Jan;57:1-9
pubmed: 25294678
EMBO J. 2001 Sep 17;20(18):5197-206
pubmed: 11566883
Nature. 2006 May 25;441(7092):437-43
pubmed: 16724055
Oncol Rep. 2017 Jul;38(1):522-528
pubmed: 28586039